Extended Data Fig. 3: Sensitivity of replication competent SARS-CoV-2 Omicron and Delta variants to clinically approved direct acting antiviral molecules remdesivir and the active metabolite of molnupiravir. | Nature

Extended Data Fig. 3: Sensitivity of replication competent SARS-CoV-2 Omicron and Delta variants to clinically approved direct acting antiviral molecules remdesivir and the active metabolite of molnupiravir.

From: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Extended Data Fig. 3

HOS cells overexpressing ACE2 and TMPRSS2 were used and a viral input of 1,000 TCID50 was used (TCID50 measured using VeroE6/TMPRSS2 cells). a. Dose-response curves. Infection as measured by viral RNA copies relative to the no drug control (100%) is plotted on the y axis with serial drug dilution on the x axis. EC50 is indicated for each panel and calculated in GraphPad Prism. Data points are mean of technical quadruplicates with +/- SEM shown. Curve fitting for dose response was done in GraphPad prism. b. toxicity assay showing relative cell viability at a range of drug doses. Data points are mean of technical quadruplicates with +/- SEM shown. All data are representative of two independent experiments.

Back to article page